26th January 2010 - Antitope Ltd. (UK) today announced a research agreement with Emory University, Atlanta (USA) for the development of an antibody therapeutic for H1N1 influenza (‘swine flu’) generated through a collaboration between researchers at Emory University and the University of Chicago. As part of the agreement, Antitope will apply its proprietary technologies towards further development of the antibody which has demonstrated efficacy in preclinical studies.
“We are honored to be collaborating with Emory University at this important time of flu pandemic” said Dr Matthew Baker, Chief Scientific Officer of Antitope Ltd. “We hope to assist Emory in the development of an important new treatment for acute H1N1 infections.”
About Antitope
Antitope Ltd. is a Cambridge UK-based biotechnology company specializing in immunogenicity testing and the engineering of therapeutic antibodies/proteins to reduce immunogenicity. Antitope's proprietary EpiScreenTM technology uses human T cells to measure the immunogenicity potential of biopharmaceuticals. Antitope's Composite Human AntibodyTM and Composite ProteinTM technologies deliver novel therapeutic antibodies and proteins with very low immunogenicity potential through the avoidance of T cell epitopes. Antitope’s expression technologies use its proprietary vector system for enhanced expression of biologics from mammalian cells. Antitope is a privately-held company and have established multiple commercial relationships with leading biotechnology and pharmaceutical companies. For further information on Antitope visit www.antitope.co.uk.
For further information contact:
Dr Neil Butt
Business Development Director, Antitope Ltd
Tel: +44 (0)1223 496190
Email: info @antitope.co.uk
Dr Neil Butt
Business Development Director, Antitope Ltd
Tel: +44 (0)1223 496190
Email: info @antitope.co.uk
